MedTrace Logo

FIRAZYR General Drug Use-Results Survey (Japan)

NCT04057131 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 179

Last updated 2025-02-21

Study results available
· View outcomes & findings →

Summary

The objectives of this survey are to collect data to report the safety and efficacy of Firazyr (Icatibant acetate) in the post-marketing phase in participants diagnosed with Hereditary Angioedema (HAE).

Conditions

  • Hereditary Angioedema (HAE)

Interventions

DRUG

Firazyr

Participants with Hereditary angioedema (HAE) receiving treatment with Icatibant acetate (Firazyr) as prescribed by their physician following locally approved prescribing information.

Sponsors & Collaborators

  • Takeda

    collaborator INDUSTRY

  • Shire

    lead INDUSTRY

Principal Investigators

  • Study Director · Takeda

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-20
Primary Completion
2024-07-29
Completion
2024-07-29

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04057131 on ClinicalTrials.gov